EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI
Ended Awarded Last action
- Contract number
- HHSN26100039
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- -$1,500,003
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 0% obligated
- $19,759,807.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Terminate for Convenience | -$1,500,003 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $8,370,414 | |
| Original award | $12,889,396 |
Show all 11
About this award
Leidos Biomedical Research Inc., a Federally Funded Research and Development Center (FFRDC) subsidiary of Leidos Holdings, Inc., was awarded a delivery order valued at $19.76 million by the National Cancer Institute on September 28, 2017, for the Retrospective Tumor Characterization Analysis (Moonshot) initiative. This cost-plus-fixed-fee delivery order, with an ultimate completion date of September 30, 2026, supports the National Cancer Institute's cancer research mission and will be performed at the company's Frederick, Maryland facility. The award carries no set-aside designation, reflecting Leidos Biomedical Research Inc.'s competitive capabilities in biomedical research and development services.
The contract incorporates specialized sub-contractor support, including nucleic acid extraction and whole exome sequencing (WES) services from the Broad Institute of MIT and Harvard (awarded July 13, 2022), which conducts high-coverage sequencing analysis on DNA isolated from archived formalin-fixed paraffin-embedded (FFPE) tumor samples and matching normal blood samples. Additional sub-contract support from Diversified Laboratory Repair Inc., a small business based in Gaithersburg, Maryland, includes facility infrastructure maintenance such as freezer window installation (awarded June 28, 2023). Together, these sub-contracted services enable Leidos to deliver comprehensive tumor analysis capabilities supporting the National Cancer Institute's cancer research portfolio.
Quick answers
Who was awarded contract HHSN26100039?
HHSN26100039 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 28, 2017.
How much is contract HHSN26100039 worth?
The government has obligated -$1,500,003 on HHSN26100039. Its current value, with exercised options, is $19,759,807.
Is contract HHSN26100039 an order under another contract?
Yes. HHSN26100039 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100039 competed?
The extent of competition for HHSN26100039 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award